Abstract #1043
Diagnostic potential of simultaneous 18 F-FACBC PET/MRI in high risk prostate cancer patients
Kirsten Margrete Selns 1,2 , Mattijs Elschot 1 , Brage Krger-Stokke 1,3 , ystein Strkersen 4 , Dag Linthoe Halvorsen 5 , Elise Sandsmark 1 , May-Britt Tessem 1,2 , Sverre Langrgen 3 , Eirik Kjbli 5 , Anders Angelsen 1 , Frode Willoch 6,7 , Helena Bertilsson 5,8 , Siver Andreas Moestue 1,2 , and Tone Frost Bathen 1,2
1
Department of Sirculation and Medical
Imaging, Norwegian University of Science and Technology,
Trondheim, Norway,
2
St.
Olavs University Hospital, Trondheim, Norway,
3
Clinic
of Radiology and Nuclear Medicine, St. Olavs University
Hospital, Trondheim, Norway,
4
Clinic
of Laboratory Medicine, St. Olavs University Hospital,
Trondheim, Norway,
5
Clinic
of Surgery, St. Olavs University Hospital, Trondheim,
Norway,
6
Institute
of Basic Medical Sciences, University of Oslo, Oslo,
Norway,
7
Aleris
Cancer Center, Oslo, Norway,
8
Department
of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology, Trondheim, Norway
The leucine amino acid analog 1-amino-3-fluorine
18-fluorocyclobutane-1-carboxylic acid (18F-FACBC) has
shown promising results in assessment of primary and
metastatic prostate cancer. In the present study a
protocol for simultaneous 18F-FACBC PET and
multiparametric MR was established and evaluated with
respect to the diagnostic potential (N-stage and grade)
in high risk prostate cancer patients. The preliminary
results show that there is high tracer uptake in regions
corresponding to tumor within the gland, however, areas
of BPH has also been observed to have high uptake.
Histopathologically verified lymph node metastasis also
show high uptake of tracer.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
